Metamark is a privately held oncology company focused on the development of molecular function-based prognostic assays for early staged cancers. The MetamarkDx? Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants?, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread.
